Penn Capital Management’s Quest Diagnostics DGX Stock Holding History

Penn Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,406	Closed	-$2.27M	–	198
2021 Q4	$2.27M	Sell	13,406 -503	-4%	-$76.5K	0.23%	124
2021 Q3	$2.02M	Sell	13,909 -2,942	-17%	-$430K	0.2%	135
2021 Q2	$2.22M	Sell	16,851 -4,267	-20%	-$559K	0.22%	129
2021 Q1	$2.71M	Buy	21,118 +27	+0.1%	+$3.33K	0.28%	107
2020 Q4	$2.51M	Sell	21,091 -1,511	-7%	-$184K	0.32%	101
2020 Q3	$2.66M	Buy	22,602 +1,995	+10%	+$236K	0.34%	125
2020 Q2	$2.41M	Sell	20,607 -274	-1%	-$29.1K	0.31%	133
2020 Q1	$1.73M	Buy	+20,881	New	+$2.16M	0.29%	135

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Penn Capital Management's DGX Position: Q1 2022 in Review

Penn Capital Management sold out of Quest Diagnostics (DGX) in Q1 2022, closing a stake of 13,406 shares — an estimated $2.27M sold.

Penn Capital Management first reported a position in DGX in Q1 2020 and held it in 8 quarters. The position peaked at $2.71M in Q1 2021. 851 funds tracked by Wall St. Rank hold DGX as of Q1 2022.

Penn Capital Management reported no remaining Quest Diagnostics position as of Q1 2022 after selling out during the quarter.
Penn Capital Management sold 13,406 Quest Diagnostics shares in Q1 2022, an estimated $2.27M.
Penn Capital Management first reported a position in Quest Diagnostics in Q1 2020 and held it in 8 quarters.
Penn Capital Management's Quest Diagnostics position peaked at $2.71M in Q1 2021.
851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2022.

Based on Penn Capital Management's 13F filing for Q1 2022, filed 17 May 2022.